Image may be NSFW.
Clik here to view.
After winning FDA approval for its muscular dystrophy drug last week, Marathon Pharmaceuticals set the drug’s list price at $89,000 a year – 50 to 70 times greater than what most U.S. patients have paid for decades by importing the drug from Europe.
Marathon’s drug is a corticosteroid, deflazacort, that has been shown to improve muscular strength in patients with a rare type of muscular dystrophy. The drug wasn’t previously sold in the U.S. because companies did not see it as profitable enough to warrant pursuing regulatory appro
Get the full story at our sister site, Drug Delivery Business News.
The post Marathon hikes MD drug price 70x to $89k a year appeared first on MassDevice.
